BAG Health Care — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

BAG Health Care is a well-established, private CDMO with over 50 years of operational history, providing specialized contract manufacturing services for sterile injectable drugs. Its core expertise lies in aseptic filling and scalable lyophilization (freeze-drying), complemented by analytical services, regulatory support, and secondary packaging, primarily catering to small and mid-sized batch requirements. The company serves the diagnostics and infectious disease sectors, leveraging its German location and GMP compliance to attract biotech and pharmaceutical clients needing reliable, agile production partners. Recent investments in new freeze-drying capacity and a strategic focus on quality assurance and niche products underscore its growth ambitions in the competitive European CDMO landscape.

Infectious DiseaseOther (Broad CDMO services)

Technology Platform

Integrated CDMO platform for sterile injectables, specializing in aseptic filling and scalable lyophilization (freeze-drying), supported by in-house analytical services, technology transfer, secondary packaging, and regulatory compliance expertise.

Opportunities

Growing demand for outsourcing from small and mid-sized biotechs, particularly for complex injectables and lyophilized products.

Increased focus on supply chain resilience and European manufacturing post-pandemic creates a favorable environment for a reliable, mid-sized EU CDMO.

The niche focus on small batches allows it to capture projects larger CDMOs may find uneconomical.

Risk Factors

Intense competition from larger global CDMOs with greater resources and capacity.

Regulatory and operational risk associated with maintaining sterile GMP compliance; any failure could be catastrophic.

Dependency on the project flow from client companies, making revenue susceptible to biotech funding cycles and client attrition.

Competitive Landscape

Operates in the highly competitive global CDMO market, competing with giants like Lonza, Catalent, and Recipharm, as well as numerous specialized European fill-finish CDMOs. Its primary competitive differentiation is its focused value proposition on flexibility and expertise in small to mid-sized batch production, combined with over 50 years of experience and a strategic location in Germany, a country synonymous with high-quality engineering and regulatory standards.

More companies in Biologics / Biosimilars →More companies in Germany →